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Dementia is one of the greatest health and social care challenges
we face, with costs set to increase substantially as the numbers
of people with dementia rise. The estimated global costs of
dementia, US$604 billion (£386 billion) in 2010, are projected
to increase by 85% by 2030.1 In England alone, the cost of long-
term care of older people with dementia is set to increase from
£5.4 billion in 2002 to £16.7 billion in 2031.2
Depression is a common and important comorbidity in
dementia. Prevalence estimates vary from 5 to 40% depending
on sampling and definition.3–5 Depression in dementia is a risk
factor for increased carer distress, disability, suicide and mortality,
and is also associated with a high level of use of medical in-patient
beds.6 Treating depression in dementia is therefore a clinical
priority with the potential to improve the well-being, quality of
life and level of function of people with dementia; it might also
have an effect on costs.
However, there is only weak evidence on the effectiveness of anti-
depressants for depression in dementia,7 and no cost-effectiveness
evidence on the treatment of depression in dementia.8 Despite
this, antidepressants are frequently used for treating depression
in dementia. The Health Technology Assessment Study of the
Use of Antidepressants for Depression in Dementia (HTA-SADD)
trial was designed to investigate the clinical effectiveness and
cost-effectiveness of the two most commonly used classes of anti-
depressants compared with placebo. We have published our
analyses of clinical effectiveness9 and reported that those
randomised to sertraline or mirtazapine did no better than those
receiving placebo. Here we report on the co-primary aim: to
examine the cost-effectiveness of sertraline and mirtazapine
compared with placebo over 13 weeks and 39 weeks in people with
depression and dementia.
Method
Research setting
We have published the details of the HTA-SADD trial method and
results elsewhere.9 To summarise, the trial involved people with
probable or possible dementia of the Alzheimer’s type according
to NINCDS-ADRDA (National Institute of Neurological and
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Background
Depression is a common and costly comorbidity in dementia.
There are very few data on the cost-effectiveness of
antidepressants for depression in dementia and their effects
on carer outcomes.
Aims
To evaluate the cost-effectiveness of sertraline and mirtazapine
compared with placebo for depression in dementia.
Method
A pragmatic, multicentre, randomised placebo-controlled trial
with a parallel cost-effectiveness analysis (trial registration:
ISRCTN88882979 and EudraCT 2006-000105-38). The primary
cost-effectiveness analysis compared differences in treatment
costs for patients receiving sertraline, mirtazapine or placebo
with differences in effectiveness measured by the primary
outcome, total Cornell Scale for Depression in Dementia
(CSDD) score, over two time periods: 0–13 weeks and 0–39
weeks. The secondary evaluation was a cost-utility analysis
using quality-adjusted life years (QALYs) computed from the
Euro-Qual (EQ-5D) and societal weights over those same
periods.
Results
There were 339 participants randomised and 326 with costs
data (111 placebo, 107 sertraline, 108 mirtazapine). For the
primary outcome, decrease in depression, mirtazapine and
sertraline were not cost-effective compared with placebo.
However, examining secondary outcomes, the time spent by
unpaid carers caring for participants in the mirtazapine group
was almost half that for patients receiving placebo (6.74 v.
12.27 hours per week) or sertraline (6.74 v. 12.32 hours per
week). Informal care costs over 39 weeks were £1510 and
£1522 less for the mirtazapine group compared with placebo
and sertraline respectively.
Conclusions
In terms of reducing depression, mirtazapine and sertraline
were not cost-effective for treating depression in dementia.
However, mirtazapine does appear likely to have been cost-
effective if costing includes the impact on unpaid carers and
with quality of life included in the outcome. Unpaid (family)
carer costs were lower with mirtazapine than sertraline or
placebo. This may have been mediated via the putative
ability of mirtazapine to ameliorate sleep disturbances and
anxiety. Given the priority and the potential value of
supporting family carers of people with dementia, further
research is warranted to investigate the potential of
mirtazapine to help with behavioural and psychological
symptoms in dementia and in supporting carers.
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Communicative Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association) criteria10 and depression
(defined as a Cornell Scale for Depression in Dementia (CSDD)11
score of over 7) referred to old age psychiatric services in nine
English sites: Birmingham, Cambridge, Leicester, Liverpool,
Manchester, Newcastle, North London, Southampton and South
London. Ethical approval was obtained from the North West 7
(Greater Manchester) Ethics Committee.
Sample size
A sample size of 507 was calculated to provide 90% power to
detect a two-point CSDD difference (s.d. = 5; standardised
effect-size (SES) = 0.4) for 13-week sertraline/placebo and
mirtazapine/placebo comparisons, and 86% power at 39 weeks.
This was revised during the trial because of slower than forecasted
recruitment to 339.9
Randomisation
After baseline assessment and consent, participants were randomised
to three groups: sertraline, mirtazapine and placebo (trial regis-
tration: ISRCTN88882979 and EudraCT 2006-000105-38). All
participants also received normal clinical care. The target doses
were 150mg sertraline or 45mg mirtazapine daily with titration
over 8 weeks. Thereafter it was open to clinicians to adjust the
dose. The Clinical Trials Unit at the Institute of Psychiatry
independently undertook treatment allocation.
Economic evaluation
The primary economic evaluation was a cost-effectiveness analysis
comparing differences in treatment costs for patients receiving
sertraline, mirtazapine or placebo with differences in effectiveness
as measured by the primary outcome, total CSDD score11 over
two time periods: 0–13 weeks and 0–39 weeks. The secondary
analysis was a cost-utility analysis using quality-adjusted life years
(QALYs) computed from the Euro-Qual (EQ-5D)12 and societal
weights (obtained from data from a sample of the general public
to aggregate items into an overall EQ-5D score)13 over those same
periods. Both the primary and secondary economic evaluations
were undertaken from two perspectives: (a) health and social care
agencies; and (b) health and social care agencies and unpaid
carers.
Resource use
Resource-use data for each person were collected over a
retrospective period of 6 months before randomisation. At 13
weeks, follow-up data were collected retrospectively for a 3-month
period and at 39 weeks for a retrospective period of 6 months.
Services and support received by the study participants were
recorded on a resource-use questionnaire adapted from the Client
Service Receipt Inventory (CSRI),14 including in-patient stays,
out-patient attendances, day hospital treatment, visits to social
clubs, meals at lunch clubs, day care visits and hours spent in
contact with community-based professionals. The study also
collected data on volunteer support, befriending and telephone
care-line support, and also on unpaid support provided by friends
and relatives. Contacts made with voluntary workers and support
provided by friends and relatives were also measured in hours of
care support time. The prescribed daily doses for the medications
were calculated from the trial medication log, and prescribing
periods were weighted to the changing dose regime.
Unit costs
All unit costs were estimated at 2009/2010 prices and were
collected from sources in the public domain (Table 1). Costs
per unit of measurement for each type of service (such as per
in-patient day, per appointment, per attendance, per visit or per
contact with health and community-based professionals including
voluntary services) were taken from a widely used compendium.15
The National Health Service Schedule of Reference Costs was used to
estimate the cost of out-patient attendances.16 The unit cost of
medication was obtained from the British National Formulary.17
We collected information from each study participant’s main
carer on time they spent providing unpaid care and support,
and time spent by friends or relatives regularly providing help
for the trial participant. We asked respondents to estimate the
hours of unpaid care and support from all such sources in an
average or typical week. Opportunity costs were attached to these
hours using, first, an estimate of replacement cost (the unit cost of
a paid local authority home care worker15) and, second, the cost
of lost employment (gross hourly wage of a carer in paid
employment; zero for a carer not in paid employment).
Cost estimation
Data on resource use from the CSRI and medication prescribed
from the medication logs were combined with unit cost data to
122
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Table 1 Unit cost for 2009–2010
Service Unit cost (£) Source
In-patient (bed days) 299 15,26
Day hospital (attendance) 50–205 15,16,26
Out-patient (appointment) 21–165 16
Accident and emergency (attendance) 37–97 15
General practitioner (per surgery consultation) 28 15
Geriatrician (min) 1.83 15
Nurse (min)a 0.43–0.52 15
Occupational therapist (min) 0.65 15
Community psychiatrist (min) 1.83 15
Counsellor (min) 0.57 15
Psychologist (min) 1.20 15
Chiropodist (contact) 0.37 15
Social worker (min) 0.67 15
Care manager (min) 0.82 15
Home care worker/care attendant (min) 0.35 15
Sitting scheme (min) 0.45 15
Self-help group (min) 0.57 15
Meals on wheels (meal) 4.8 b
Dentist (min) 2.90 16
Optician (min) 0.48 c
Day care (day) 42–66 15
Lunch club (meal) 7 d
Social club (session) 5 e
a. Practice nurse, district nurse health visitor, community psychiatric nurse, cardiac
nurse, incontinence nurse.
b. http://www.ic.nhs.uk/webfiles/publications/009_Social_Care/pss0910expfinal/
pss0910updateOct2011/Personal_Social_Services_Expenditure_Report_2009_10.pdf
c. New calculation: there is a recommended fee payable to ophthalmic medical
practitioners who administer sight tests, although optometrists undertake most tests.
Optometrist salaries vary depending on practice setting (private or hospital or
combination of the two). Typical salaries in private practice based on salary data
collected June 2009 (http://www.prospects.ac.uk/optometrist_salary.htm) ranged from
£19 500 to £28 000. In hospital settings, optometrist salaries are usually covered by
the Agenda for Change pay scale. Average salary for private practice was used.
Cost per hour was estimated based on 41 weeks per annum, 38 hours per week.
d. http://cash-online.org.uk/content/1/6/3/; uprated using the Consumer Price Index
(CPI).15
e. Cost of adult social club at 2004/05 uprated using the pay and prices inflator.15
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estimate total costs for each participant in the trial. Three main
categories of costs were analysed: medication costs, aggregated
health and social care costs (primary care and hospital-based visits
and community-based contacts) and (opportunity) cost of time
spent caregiving by relatives and friends. Costs were categorised
in this way to facilitate comparison of costs alongside measures
of effectiveness from the various study perspectives. The costs of
services and support used by patients were derived by combining
medication, health and social care resource utilisation data with
unit costs. Costs were calculated for the periods 0–13 weeks and
0–39 weeks.
Statistical analysis
An ‘intention-to-treat’ analysis was carried out to preserve the
unbiased distribution of factors in the groups produced by
randomisation. Missing resource-use data were singly imputed.
If there was no report on the use of a particular resource, we
assumed that it was not used. If participants reported on a
resource but not the quantity used, we imputed this amount from
within treatment-group means for participants with data for that
item at the same assessment point.
Health and social care costs for 0–13 weeks and 0–39 weeks
(and health/social care and costs of unpaid carer costs for the
parallel analysis from the broader perspective for the same time
periods) were regressed in turn on treatment allocation, baseline
cost, baseline CSDD and centre. To mitigate the effects of
skewness, non-parametric bootstrapping methods were used to
estimate 95% confidence intervals (CIs) for mean costs. Where the
bias-corrected 95% CIs of between-group change scores excluded
zero, they could be judged to be significant at P=0.05 or lower.
Estimates of bootstrapped mean cost and effectiveness were
used to estimate an incremental cost-effectiveness ratio (ICER)
for each analysis. The ICER for each replication was calculated as:
(costb7costa)/(effectb7effecta),
which summarises the cost difference between two treatments per
incremental difference in the outcome (CSDD and EQ-5D in
turn). The EQ-5D was measured directly from patients – as
recommended by National Institute for Health and Clinical
Excellence (NICE) guidelines18 – and weighted by a valuation of
changes in quality of life reported from UK population data.13
Health effects were then expressed in terms of QALYs. The ratio
statistic compared the treatments in terms of observed differences
in costs and effects, regardless of whether those differences were
statistically significant.
Uncertainty about the cost and effectiveness estimates was
addressed by plotting cost-effectiveness acceptability curves
(CEAC). A CEAC was used to assess trade-offs between costs
and outcomes, showing the likelihood of each of the two
medications in turn being seen as cost-effective relative to the
other or relative to placebo, given different (implicit monetary)
values placed on incremental outcome improvements. In this
net-benefit approach, monetary values of incremental effects
and incremental costs for each case are combined, and the net
benefit derived as:
NB=l6(effectb7effecta)7(costb7costa),
where: a is the comparator, b is drug treatment, NB is net benefit,
and l is willingness to pay for a unit improvement in CSDD-
depression severity score (primary evaluation) or an additional
QALY (secondary evaluation). The impact on costs given
uncertainty around the value attached to informal care inputs
was assessed in one-dimensional sensitivity analysis. All analyses
were completed in Stata (version 11) and SPSS 17 on Windows.
Results
Baseline comparisons
Overall, 339 participants were recruited to the trial. At baseline,
full service-use data were available for 326 participants (111
placebo, 107 sertraline, 108 mirtazapine). At 13 weeks, economic
data were available for 97 (87%) participants in the placebo group,
78 (73%) in the sertraline group and 88 (81%) in the mirtazapine
group. By 39 weeks there were economic data on 84 (76%)
participants in the placebo group, 69 (64%) in the sertraline group
and 78 (72%) in the mirtazapine group. This drop-out level is
comparable with other trials in the area.
Service use and support
Contacts made by study participants with services and support
over weeks 0–13 and 0–39 are shown in Tables 2 and 3
respectively. In the 0–13-week period (Table 2), there were no
differences in service use between the treatment groups reaching
statistical significance at the 5% level. However, taking the whole
0–39 week period (Table 3), it was striking that the mean number
of hours per week spent by unpaid carers caring for patients in the
placebo-treated group and the sertraline group were almost twice
that for patients in the mirtazapine-treated group. This difference
in unpaid carer time between the placebo and mirtazapine-treated
group was statistically significant at the 5% level.
Outcomes
At 39 weeks, the difference inmean CSDD score between placebo and
sertraline was 0.05 (95% CI 71.83 to 1.67); between placebo and
mirtazapine was 70.80 (95% CI 72.55 to 1.21); and between
mirtazapine and sertraline was 70.9 (95% CI71.10 to 2.73). The
secondary measure of outcome was QALY gain at 39 weeks; the mean
difference between placebo and sertraline was 0.03 (95% CI70.09 to
0.03); between placebo and mirtazapine was 0.05 (95% CI70.10 to
0.01); and between mirtazapine and sertraline was 0.02 (95% CI
70.03 to 0.07). There were no statistically significant differences
in either the primary or secondary measure of outcome between
groups at 39 weeks (or at 13 weeks) (Table 4).
Costs
Daily medication costs for sertraline 50mg of £0.05 and mirtazapine
15mg of £0.23 were applied (mean cost of medication per person:
£7 (95% CI 6–8) and £37 (95% CI 32–41)). Mean total costs over
0–13 weeks and 0–39 weeks are detailed in Table 4. Pair-wise
comparisons were made between the two antidepressants and
placebo using regression analysis and bootstrapping. There were
no statistically significant differences between the groups in either
of the time periods, either when health and social care service
costs only were considered, or when health and social care services
and unpaid carer costs were summed. After adjustment for
baseline costs, CSDD score at baseline and site, there were no
statistically significant differences in health and social care costs
– or in health/social care and unpaid carer costs – in any pair-wise
comparison in either time period.
Unpaid carer costs exceeded health and social care costs by a
factor of 1.2 to 1.7. Including these unpaid carer costs results in
a change in the ranking of total costs, with mirtazapine being
the least expensive of all treatments in both periods.
Cost-effectiveness
As noted earlier, the primary economic evaluation focused on
CSDD as the outcome over, first, the period 0–13 weeks after
randomisation, and, second, the period 0–39 weeks after
123
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Table 2 Service use, week 0–13
Placebo (n=97) Sertraline (n=78) Mirtazapine (n=88)
n Meana (s.d.) n Meana (s.d.) n Meana (s.d.)
Hospital-based care
In-patient (bed day)b 8 1.65 (7.98) 5 1.58 (6.82) 5 0.49 (2.19)
Out-patient (attendance) 33 0.53 (1.08) 25 0.60 (1.10) 26 0.53 (1.10)
Accident and emergency (attendance) 8 0.12 (0.48) 5 0.08 (0.27) 4 0.57 (0.28)
Day hospital (contact) 3 0.23 (1.44) 6 0.83 (4.11) 4 0.32 (1.66)
Community-based care
General practitioner (contact) 57 1.36 (2.36) 44 1.09 (1.44) 49 1.22 (2.84)
Geriatrician (contact) 3 0.03 (0.17) 0 0 88 0.03 (0.18)
Nursec (contact) 41 0.87 (1.49) 29 2.50 (10.83) 43 1.56 (3.71)
Occupational therapist (contact) 11 0.21 (0.66) 7 0.35 (1.70) 5 0.08 (0.38)
Community psychiatrist (contact) 21 0.26 (0.54) 14 0.24 (0.63) 19 0.27 (0.58)
Psychologist (contact) 2 0.82 (0.64) 3 0.06 (0.37) 2 0.09 (0.62)
Counsellor (contact) 1 0.01 (0.10) 3 0.36 (2.94) 2 0.17 (1.32)
Care manager (contact) 7 0.10 (0.42) 1 0.01 (0.11) 4 0.05 (0.21)
Social worker (contact) 15 0.21 (0.69) 10 0.19 (0.58) 12 0.28 (0.87)
Home care worker/care attendant (contact) 19 18.57 (60.57) 17 21.92 (72.77) 22 28.33 (72.19)
Chiropodist (contact) 33 0.43 (0.71) 16 0.26 (0.57) 23 0.40 (0.88)
Sitting scheme (contact) 5 1.21 (6.71) 5 0.68 (4.29) 3 0.59 (3.75)
Self-help group (contact) 0 0 0 0 1 0.03 (0.32)
Meals on wheels (contact) 3 0.30 (1.77) 3 5.82 (33.95) 4 2.32 (12.74)
Dentist (contact) 10 0.13 (0.49) 10 0.15 (0.43) 15 0.23 (0.58)
Optician (contact) 10 0.12 (0.39) 13 0.19 (0.46) 12 0.15 (0.39)
Day services
Day services (day) 15 4.15 (11.95) 17 6.50 (15.64) 16 5.47 (13.33)
Lunch club (visit) 3 1.88 (15.92) 0 0 3 1.18 (8.51)
Social club (visit) 2 0.27 (1.86) 4 0.67 (2.89) 2 0.44 (3.08)
Informal care
Care giving (hours/week) 45 10.05 (17.65) 37 11.63 (21.59) 42 9.84 (23.85)
a. Across full sample.
b. Psychiatric and non-psychiatric in-patient bed days.
c. Practice nurse, district nurse health visitor, community psychiatric nurse, cardiac nurse, incontinence nurse.
Table 3 Service use, week 0–39
Placebo (n=84) Sertraline (n=69) Mirtazapine (n=78)
n Meana (s.d.) n Meana (s.d.) n Meana (s.d.)
Hospital-based care
In-patient (bed day)b 9 3.05 (10.48) 11 2.55 (9.26) 14 4.54 (15.08)
Out-patient (attendance) 44 0.83 (1.15) 33 0.90 (1.41) 29 0.69 (1.15)
Accident and emergency (attendance) 13 0.17 (0.41) 8 0.25 (0.86) 7 0.10 (0.35)
Day hospital (contact) 1 0.01 (0.11) 8 2.61 (9.42) 3 0.56 (3.30)
Community-based care
General practitioner (contact) 57 1.51 (1.83) 40 1.52 (2.15) 55 1.88 (2.40)
Geriatrician (contact) 4 0.05 (0.21) 0 0 2 0.03 (0.16)
Nursec (contact) 37 1.24 (2.34) 33 5.84 (29.57) 34 1.46 (3.53)
Occupational therapist (contact) 9 0.17 (0.53) 8 0.45 (2.23) 5 0.10 (0.44)
Community psychiatrist (contact) 22 0.33 (0.67) 15 0.26 (0.53) 29 0.60 (1.48)
Psychologist (contact) 5 0.21 (1.34) 2 0.03 (0.17) 1 0.01 (0.11)
Care manager (contact) 6 0.52 (2.87) 3 0.04 (0.21) 5 0.10 (0.44)
Social worker (contact) 12 0.58 (2.98) 15 0.42 (0.98) 17 0.44 (1.47)
Home care worker/care attendant (contact) 16 33.56 (107.73) 19 38.07 (95.60) 17 38.95 (110.10)
Chiropodist (contact) 35 0.88 (1.37) 20 0.53 (1.52) 32 1.11 (1.89)
Sitting scheme (contact) 0 0 5 1.23 (5.49) 4 0.76 (3.69)
Meals on wheels (contact) 2 0.63 (5.67) 2 3.77 (21.70) 2 3.14 (19.49)
Dentist (contact) 18 0.33 (0.96) 18 0.47 (1.25) 19 0.34 (0.81)
Dietician (contact) 0 0 0 0 1 0.01 (0.11)
Day services
Day services (day) 16 5.57 (14.31) 18 7.26 (15.13) 16 5.17 (12.63)
Lunch club (visit) 1 0.31 (2.84) 1 0.38 (3.15) 3 0.83 (4.84)
Social club (visit) 2 0.62 (4.47) 3 0.57 (2.69) 1 0.33 (2.94)
Informal care
Care giving (hours per week) 40 12.27 (21.24) 34 12.32 (24.07) 33 6.74 (11.82)
a. Across full sample.
b. Psychiatric and non-psychiatric in-patient bed days.
c. Practice nurse, district nurse health visitor, community psychiatric nurse, cardiac nurse, incontinence nurse.
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randomisation. The secondary evaluation focused on QALYs
computed from the EQ-5D and societal weights over the same
periods. Data used in the estimation of the ICERs are shown in
Table 5. As noted earlier, there were no statistically significant
differences in CSDD scores or QALYs in any of the pair-wise
comparisons. There were also no significant pair-wise differences
in costs from either perspective between the treatment groups.
Probability estimates were plotted for a range of implicit
monetary values attached to improvements in depression score
and QALY gain. We are not aware of any studies that have
attached monetary values to incremental changes in CSDD to
provide any guidance on the appropriate range of willingness-
to-pay values.
In Fig. 1, we see that mirtazapine had a low likelihood (around
30%) of being more cost-effective than placebo if society were not
willing to pay anything for a unit improvement in the CSDD
depression score. The likelihood of cost-effectiveness rose to
80% if society were willing to pay £5000 for a unit improvement
in CSDD score, and stayed at 80% over values of willingness to
pay for an improvement in CSDD score up to £30 000.
Figure 2 shows the CEACs from the secondary economic
evaluation, where health and social care costs including unpaid
carer inputs and health and social care costs excluding unpaid
carer inputs were considered alongside QALYs in turn. It suggests
that from a health and social care perspective mirtazapine was
125
T
a
b
le
4
H
e
a
lt
h
a
n
d
s
o
c
ia
l
c
a
re
a
n
d
in
fo
rm
a
l
c
a
re
c
o
s
ts
a
n
d
o
u
tc
o
m
e
P
la
ce
b
o
S
e
rt
ra
lin
e
M
ir
ta
za
p
in
e
B
o
o
ts
tr
a
p
p
e
d
m
e
a
n
d
if
fe
re
n
ce
(9
5
%
C
I)
n
M
e
a
n
(s
.d
.)
,
£
n
M
e
a
n
(s
.d
.)
,
£
n
M
e
a
n
(s
.d
.)
,
£
S
e
rt
ra
lin
e
–
p
la
ce
b
o
M
ir
ta
za
p
in
e
–
p
la
ce
b
o
M
ir
ta
za
p
in
e
–
se
rt
ra
lin
e
(a
)
M
e
d
ic
at
io
n
co
st
s
0–
13
w
e
e
ks
97
0
78
7
(5
)
88
37
(2
2)
7
(6
to
8)
37
(3
2
to
41
)
30
(2
5
to
34
)
0–
39
w
e
e
ks
84
0
69
7
(5
)
78
37
(2
2)
7
(6
to
8)
37
(3
2
to
41
)
30
(2
5
to
34
)
(b
)
H
e
al
th
an
d
so
ci
al
ca
re
co
st
s
0–
13
w
e
e
ks
97
14
38
(3
33
9)
78
14
34
(2
32
6)
88
10
94
(1
87
1)
7
4
(7
90
0
to
79
8)
7
34
4
(7
12
07
to
32
2)
7
34
0
(7
10
49
to
28
3)
0–
39
w
e
e
ks
84
21
46
(4
40
2)
69
28
32
(4
11
1)
78
25
13
(4
29
0)
68
6
(7
63
0
to
19
73
)
36
7
(7
97
7
to
15
96
)
7
31
9
(7
16
43
to
10
23
)
(c
)
In
fo
rm
al
ca
re
co
st
0–
13
w
e
e
ks
97
27
44
(4
81
9)
78
31
75
(5
89
7)
88
26
87
(6
51
1)
43
1
(7
10
00
to
22
42
)
7
57
(7
16
86
to
15
37
)
7
48
8
(7
23
80
to
14
70
)
0–
39
w
e
e
ks
84
33
51
(5
79
9)
69
33
63
(6
57
3)
78
18
41
(3
22
8)
12
(7
19
40
to
22
56
)
7
15
10
(7
30
88
to
7
13
6)
7
15
22
(7
33
98
to
7
72
)
To
ta
l
co
st
s
e
xc
lu
d
in
g
in
fo
rm
al
ca
re
in
p
u
ts
(a
+
b
)
0–
13
w
e
e
ks
97
14
38
(3
33
9)
78
14
41
(2
32
7)
88
11
31
(1
86
9)
3
(7
89
3
to
80
6)
7
30
7
(7
11
72
to
35
8)
7
31
0
(7
91
0
to
29
9)
0–
39
w
e
e
ks
84
21
46
(4
40
2)
69
28
39
(4
11
2)
78
25
50
(4
28
9)
69
3
(7
62
2
to
19
80
)
40
4
(7
97
2
to
16
26
)
7
28
9
(7
15
45
to
11
51
)
To
ta
l
co
st
s
in
cl
u
d
in
g
in
fo
rm
al
ca
re
in
p
u
ts
(a
+
b
+
c)
0–
13
w
e
e
ks
97
41
82
(5
82
1)
78
46
16
(6
48
8)
88
38
18
(7
06
0)
43
4
(7
13
40
to
23
56
)
7
36
5
(7
22
12
to
15
60
)
7
79
8
(7
27
54
to
14
98
)
0–
39
w
e
e
ks
84
54
97
(7
92
2)
69
62
02
(8
24
1)
78
43
91
(5
28
5)
70
5
(7
18
55
to
32
34
)
7
11
06
(7
31
37
to
97
0)
7
18
11
(7
40
48
to
54
3)
D
e
p
re
ss
io
n
sc
o
re
(C
SD
D
)
13
w
e
e
ks
95
7.
8
(4
.1
)
78
8.
6
(4
.9
)
85
7.
9
(5
.0
)
0.
84
(7
0.
60
to
2.
14
)
0.
16
(7
1.
53
to
1.
11
)
7
0.
7
(7
0.
57
to
2.
52
)
39
w
e
e
ks
82
8.
5
(5
.5
)
68
8.
6
(5
.5
)
76
7.
7
(6
.2
)
0.
05
(7
1.
83
to
1.
67
)
7
0.
80
(7
2.
55
to
1.
21
)
7
0.
9
(7
1.
10
to
2.
73
)
Q
A
LY
39
w
e
e
ks
(E
Q
-5
D
)
57
0.
55
(0
.1
7)
53
0.
57
(0
.1
4)
52
0.
60
(0
.1
3)
0.
03
(7
0.
09
to
0.
03
)
0.
05
(7
0.
10
to
0.
01
)
0.
02
(7
0.
03
to
0.
07
)
C
SD
D
,
C
o
rn
e
ll
Sc
al
e
fo
r
D
e
p
re
ss
io
n
in
D
e
m
e
n
tia
;
Q
A
LY
,
q
u
al
ity
-a
d
ju
st
e
d
lif
e
ye
ar
s;
E
Q
-5
D
,
E
u
ro
-Q
u
al
.
100 –
90 –
80 –
70 –
60 –
50 –
40 –
30 –
20 –
10 –
0 –
0 1000 5000 10 000 15 000 20 000 25 000 30 000
Willingness to pay for a point improvement in depression
(CSDD), £
P
ro
b
ab
ili
ty
is
co
st
-e
ff
e
ct
iv
e
re
la
tiv
e
to
p
la
ce
b
o
,
%
Fig. 1 Probability that mirtazapine is cost-effective compared
with placebo: health and social care costs and Cornell Scale for
Depression in Dementia score (CSDD) over 39 weeks.
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14% likely to be more cost-effective than placebo even if society
were willing to pay nothing for a QALY gain. This probability
increased to over 20% for a willingness to pay £30 000 for a QALY
gain. However, when health and social care costs including unpaid
carer inputs were considered alongside QALYs, mirtazapine was
89% likely to be more cost-effective than placebo even if society
were willing to pay nothing for a QALY gain. The £30 000 value
is important as it is the threshold often associated with positive
decisions on health technologies taken by NICE.
We assessed uncertainty around parameter estimates included
in the cost analysis. For the main analyses, unpaid carer costs were
based on the hourly cost of a home care worker. This hourly value
for the caregiving inputs by friends and family was replaced in
sensitivity analysis by the gross hourly wage of a carer in paid
employment and zero for a carer not in paid employment. Using
these alternative values of caregiver time inputs did not alter the
findings (Table 6).
Discussion
As far as we are aware this is the first study to explore the cost-
effectiveness of mirtazapine and sertraline in treating depression
in dementia. Our results show that mirtazapine and sertraline
are not cost-effective compared with placebo as a treatment for
depression in dementia when looking at the primary outcome of
change in depressive symptoms (i.e. neither of the antidepressants
reduced CSDD score more than placebo).
However, mirtazapine did halve unpaid carer time and
therefore carer costs. So, when costs were considered alongside
QALY gains, a different picture emerged. Mirtazapine had the
highest likelihood of cost-effectiveness compared with sertraline
and placebo. Some previous studies have similarly reported a
cost-effectiveness advantage when using the QALY as the outcome
measure even though there was no discernible cost-effectiveness
difference on the primary symptom measure, including studies of
dementia19 and depression.20 The probabilities of cost-effectiveness
at a willingness-to-pay value of £30 000 per QALY and under are
relevant given that NICE uses this value as a threshold to guide
decisions about whether or not to recommend health technologies.21
We considered possible reasons for the finding that mirtazapine
treatment had a good chance of being cost-effective compared with
placebo or sertraline when the outcome under consideration is
QALY. The trend towards lower incremental costs for mirtazapine
was driven by the statistically significantly lower unpaid carer
inputs. The small improvements in quality of life for mirtazapine
relative to the other treatments also contributed to the cost-
effectiveness result, and can perhaps be mediated plausibly via
the putative ability of mirtazapine to ameliorate sleep disturbances
and anxiety.22,23 Improvements in sleep could potentially improve
life quality and therefore patient-reported EQ-5D scores; they
could also release carer time directly and so ameliorate an
important source of carer distress.24 In this way mirtazapine might
have a general effect, beneficial for both the patient and the carer,
without exerting a specific antidepressant effect. The extent to
which this is generalisable to other antidepressants is not clear
from our study. The potential positive effects of mirtazapine act
more in the realm of general behavioural and psychological
symptoms in dementia than depression per se. It is possible that
a positive effect on sleep, anxiety or agitation in the person with
dementia might result in relief, not only for the person with
dementia but also the carer, in terms of hours of care needed.
However, it is also important to note that complex ethical issues
are raised potentially when treatment is given to patients for the
benefit of their carers.
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Cost-effectiveness analyses for mirtazapine and sertraline in dementia
Strengths and limitations of the study
This is the first randomised controlled trial with an economic
evaluation of pharmacotherapy for people with dementia and
depression, based on individual patient data, and so fills an
important evidence gap. Further, its findings are likely to have a
wide application because of the broad nature of the study group,
in terms of both the range of depressive symptoms and the
severity of dementia. The study included individuals with
probable and possible Alzheimer’s. This group is close to the
population found in clinical practice where there is often a
vascular component to dementia. However, we would limit
generalisability of the study’s findings to those with Alzheimer’s
disease and mixed dementia only, and not to other subtypes
such as vascular dementia, dementia with Lewy bodies or
frontotemporal dementia.
There were some incomplete data from the CSRI, which was
to be expected given the size and spread of the sample and the
comprehensive nature of the service-use data-collection exercise.
It would not have been feasible to collect these data from
alternative sources. Missing responses were therefore assigned a
value by imputation to make efficient use of the data provided.
The computation of unpaid carer costs is always difficult and
we built estimates in this study on two different assumptions
about unit cost, and did not reach different conclusions about
cost-effectiveness. However, we were still reliant on carers’ self-
reported numbers of hours spent providing support to trial
participants, and this is an aspect of evaluation that needs more
attention to ensure sufficient accuracy.
Implications
Following the current policy-making stance of focusing on health
and social care costs, the findings reported here suggest that using
these drugs (relative to placebo) for treating depression in
dementia is unlikely to be cost-effective if a narrow focus on
depression score is adopted. However, treatment with mirtazapine
appears likely to be cost-effective if a broad cost-perspective is
used (to include the impact on health and social care services
and the impact on unpaid carers) and if a broader approach is
taken to outcome measurement to look at health-related quality
of life. Family carers are a vital resource in dementia care and their
support is an explicit policy priority in England.25 Given the
priority and the potential value of supporting family carers of
people with dementia, further research is warranted to investigate
the potential of mirtazapine to help with behavioural and
psychological symptoms in dementia and in supporting carers.
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Shoplifting
Martin S. Humphreys
Shoplifting is common. The Centre for Retail Research estimates that customer and staff theft in the UK accounted for nearly
£4000 million in 2011 alone. Generally there is no link with mental disorder. But it can be associated with depression, often in
apparently well-adjusted, law-abiding women, in middle or later life and what appears to be a conventional marriage.
Characteristically in such cases it occurs in a major high street retailer, is of an unwanted item that the perpetrator possesses
the funds to buy, which is removed if not ostentatiously, then with no attempt at concealment. A cry for help?
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